% Expired Patents = 25.0

EPO Patents = 1

Forward Citations = 35

Loading Chart...

11 inventors (with patents filed for the assignee):

Pamela T Manning (7 out of 10 patents)

Hwai Wen Chang (4 out of 58 patents)

Gerhard Johann Frey (4 out of 87 patents)

4. William A Frazier (4 out of 14 patents)

5. Robyn Puro (4 out of 4 patents)

6. Juan C Almagro (4 out of 28 patents)

7. Robert W Karr (4 out of 5 patents)

8. Ronald R Hiebsch (1 out of 1 patent)

9. Benjamin J Capoccia (1 out of 1 patent)

10. Gabriela Andrejeva (1 out of 1 patent)

11. Daniel S Pereira (1 out of 1 patent)

8 patents: Sort by Forward Citations

1. 11692035 - Therapeutic CD47 antibodies (2023-07-04),

2. 11292834 - Therapeutic CD47 antibodies (2022-04-05),

3. 11202828 - Therapeutic SIRP-α antibodies (2021-12-21),

4. 10844124 - Therapeutic CD47 antibodies (2020-11-24),

5. 10676524 - Therapeutic CD47 antibodies (2020-06-09),

6. 10669336 - Therapeutic CD47 antibodies (2020-06-02),

7. 10259873 - Therapeutic CD47 antibodies (2019-04-16),

8. 10239945 - Therapeutic CD47 antibodies (2019-03-26),

Arch Oncology is a clinical-stage immuno-oncology company focused on the discovery and development of antibody-based therapeutics for the treatment of solid tumors. The company's lead product candidate, AO-176, is being evaluated in multiple clinical trials for various cancer indications.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

8 Patents

#21 in Brisbane, CA

#8,528 in California

#35,865 in US

Brisbane, CA, United States of America

Arch Oncology, Inc.